Markets
Hims & Hers Health CEO Andrew Dudum
Hims & Hers CEO Andrew Dudum (Business Wire)

Hims expands into testosterone treatments

The company will start with compounded enclomiphene, with more treatments to come in 2026.

J. Edward Moreno

Hims & Hers rose more than 5% on Wednesday morning after it announced that it has expanded into testosterone treatments after teasing the new category earlier this year.

Starting Wednesday, Hims providers will be able to prescribe compounded enclomiphene, an oral off-label testosterone treatment, which the company says it can combine with tadalafil, a treatment for erectile dysfunction. Hims also said that it plans next year to introduce injectable testosterone and partner with Marius Pharmaceuticals to provide Kyzatrex, a branded and FDA-approved oral testosterone treatment.

Investors have been eager for signs of revenue growth at Hims. In its annual shareholder letter, Hims said it would expand into hormone treatments for testosterone and menopause by the end of the year.

Hims patients will start with an at-home blood test. In February, the company acquired Trybe Labs, a blood-testing facility that gives patients results in days. Prescriptions for enclomiphene will be dispensed by both partner and Hims-owned pharmacies.

I tried signing up for a prescription of compounded enclomiphene (which is not available in New York, where I live) and was quoted $990 for a 10-month plan, which includes the cost of the at-home tests.

Hims saw a boom in compounded GLP-1 sales while those branded drugs were in shortage, but since the supply constraints eased earlier this year, the company has been limited in how much of the blockbuster weight-loss drugs it can sell. Last month, it reported quarterly revenue numbers that missed Wall Street estimates and fell quarter to quarter for the first time ever.

The partnership with Marius also helps bolster the company’s vision as the “Netflix of healthcare” — a narrative that got dimmed after its epic falling out with Novo Nordisk. The exclusivity of the partnership with Marius “pertains specifically to the private label aspect of the partnership,” a spokesperson for the pharmaceutical company told Sherwood News.

More Markets

See all Markets
markets
Luke Kawa

Opendoor surges on bullish options bets as traders look to potential real estate tokenization

Opendoor Technologies is surging on Friday amid bullish options bets and social media posts referencing unconfirmed rumors about the company.

The stock moved higher in the premarket session after the soft inflation report boosted stocks and briefly pushed long-term bond yields lower (positive for a real estate company). But the real gains came after the opening bell rang and options demand picked up.

As of 12:11 p.m. ET, roughly 664,000 call options have changed hands versus a 10-day average of about 364,000 for a full session.

What seems to be galvanizing members of the “$OPEN Army” is the potential for the company to pursue the tokenization of real-world assets, with Robinhood often bandied about as a potential partner in this endeavor.

(Robinhood Markets Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Opendoor bulls have often pointed to signs that Robinhood CEO Vlad Tenev appears to be fond of the company, from what appeared on-screen during a demo of a social trading feature at HOOD’s conference in Las Vegas in September to offering support to Opendoor CEO Kaz Nejatian in setting up an opportunity for retail shareholders to ask questions during the online real estate company’s next earnings call.

Opendoor is currently in a quiet period ahead of earnings, which restricts what type of announcements a company can make.

The call options seeing the most demand expire this Friday with strike prices of $8, $8.50, and $9.

Intel Earnings Researchers

Wall Street analysts see some issues with Intel’s earnings

Even with the US government as a partial owner, Intel’s turnaround has a long way to go.

markets
Luke Kawa

Beyond Meat gains amid slightly better-than-expected Q3 sales, positive commentary on legal issues

Shares of Beyond Meat built on their premarket gains after the plant-based meat seller reported preliminary Q3 sales a bit ahead of Wall Street’s expectations, before paring this advance after the market opened.

For the three months ended September 27, management said net revenue would be approximately $70 million. That’s in line with their guidance range of $68 million to $73 million, but Wall Street was expecting sales to skew toward the lower end of that range, at $68.7 million.

However, its anticipated gross margin of 10% to 11% is lower than analysts had been expecting (13.8%). That’s still the case even adjusting for expenses related to its downsizing of operations in China, which would have left margins around 12% to 13%, per Beyond.

Perhaps more importantly, the company provided positive commentary regarding arbitration discussions with a former co-manufacturer that appear to bring it closer to a resolution while limiting potential damages:

“As previously disclosed, in March 2024, a former co-manufacturer brought an action against the Company in a confidential arbitration proceeding claiming that the Company inappropriately terminated its agreement with the co-manufacturer and claimed damages of at least $73.0 million. On September 15, 2025, the arbitrator issued an interim award (the ‘Interim Award’) and found that the Company had a valid basis to terminate the agreement with the Manufacturer. The details of the Interim Award are confidential, and a final arbitration award has not been issued. Additional proceedings will be held to determine the award of attorneys’ fees, prejudgment interest and costs, if any, before a final arbitration award will be issued. On September 25, 2025, the Manufacturer filed a request with the arbitrator to re-open the arbitration hearing. On September 29, 2025, the Company opposed this request. On October 20, 2025, the arbitrator denied the Manufacturer’s request.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.